Efficacy of Intraperitoneal Administration of PEGylated NELL-1 for Bone Formation
Open Access
- 1 June 2016
- journal article
- research article
- Published by SAGE Publications in BioResearch Open Access
- Vol. 5 (1) , 159-170
Abstract
Systemically delivered NEL-like molecule-1 (NELL-1), a potent pro-osteogenic protein, promotes bone formation in healthy and osteoporotic mouse models. PEGylation of NELL-1 (NELL-PEG) increases the half-life of the protein in a mouse model without compromising its osteogenic potential, thereby improving its pharmacokinetics upon systemic delivery. This study consists of a twofold approach: a biodistribution test and an in vivo osteogenic potential test. The biodistribution test compared two commonly used administration methods for drug delivery other than intravenous—intraperitoneal (IP) and subcutaneous (SC)—to examine NELL-PEG biodistribution in mice. Compared to a single-dose SC injection (1.25 mg/kg), a single-dose IP administration yielded a higher protein uptake in the targeted bone sites. When the IP injection dose was doubled to 2.5 mg/kg, the protein remained in the femurs, tibias, and vertebrae for up to 72 h. Next, based on the results of the biodistribution study, IP administration was selected to further investigate the in vivo osteogenic effects of weekly NELL-PEG injection (q7d). In vivo, the IP administered NELL-PEG group showed significantly greater bone mineral density, bone volume fraction, and trabecular bone formation in the targeted bone sites compared to the phosphate-buffered saline control. In summary, weekly NELL-PEG injection via IP administration successfully enhanced the overall bone quality. These findings demonstrate that systemic delivery of NELL-PEG via IP administration may serve as an effective osteogenic therapy for preventing and treating osteoporosis.Keywords
This publication has 49 references indexed in Scilit:
- NELL-1 increases pre-osteoblast mineralization using both phosphate transporter Pit1 and Pit2Biochemical and Biophysical Research Communications, 2012
- A new function of Nell-1 protein in repressing adipogenic differentiationBiochemical and Biophysical Research Communications, 2011
- Nfatc2 is a primary response gene of nell-1 regulating chondrogenesis in ATDC5 cellsJournal of Bone and Mineral Research, 2010
- Nell-1, a key functional mediator of Runx2, partially rescues calvarial defects in Runx2 +/− miceJournal of Bone and Mineral Research, 2010
- Genome-wide pleiotropy of osteoporosis-related phenotypes: The framingham studyJournal of Bone and Mineral Research, 2010
- Adverse Effects of Bisphosphonates: Implications for Osteoporosis ManagementMayo Clinic Proceedings, 2009
- Patients’ preferences for osteoporosis drug treatment: a discrete choice experimentOsteoporosis International, 2008
- A Study of the Role of Nell-1 Gene Modified Goat Bone Marrow Stromal Cells in Promoting New Bone FormationMolecular Therapy, 2007
- Molecular and cellular mechanisms of the anabolic effect of intermittent PTHBone, 2007
- The use of 18F-fluoride and 18F-FDG PET scans to assess fracture healing in a rat femur modelEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007